Compare Lumen Technologies Inc (LUMN) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Repligen Corporation Common Stock — how do they compare? Lumen Technologies Inc trades at $4.52 (market cap $4.69B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 2.4× Lumen Technologies Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Repligen Corporation Common Stock for 0 Days on average.
| LUMN | RGEN | |
|---|---|---|
Market Cap | $4.69B | $11.31B |
Volume | 25,477,875 | 1,216,919 |
Sector | Media | Health |
52-Week High | $11.83 | $194.57 |
52-Week Low | $4.55 | $102.87 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $16.31B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $4.99, down 1.19% on the day, with a bearish technical outlook and mixed earnings history. Revenue has declined from $17.5B in 2022 to $12.4B in 2025, with a net loss of $1.74B last year. The company is pivoting to AI and digital networking services, recently announcing a Nasdaq listing and launching Intelligent Internet to capture enterprise demand.
The stock presents a high-risk turnaround opportunity, with deep value indicated by a low P/S of 0.42 but significant challenges including high debt, negative margins, and analyst skepticism. Strategic growth in AI services offers potential upside, but legacy declines and financial instability pose substantial risks for investors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
